Phase I/II Study of R340 (Capecitabine), L-OHP (Oxaliplatin) and R435 (Bevacizumab) in Advanced and/or Metastatic Colorectal Cancer.
Latest Information Update: 03 Nov 2021
Price :
$35 *
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine; Oxaliplatin
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Chugai Pharmaceutical
- 13 Aug 2010 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
- 13 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 Sep 2009 Data were submitted to the Japanese Ministry of Health, Labour and Welfare (MHLW) in February 2008, and approval for the use of capecitabine in patients with advanced/refractory colorectal cancer was granted on 18 Sept. 2009.